Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Debt (2024 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Non-Current Debt for 2 consecutive years, with $21.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 26.98% to $21.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.8 million through Dec 2025, down 26.98% year-over-year, with the annual reading at $21.8 million for FY2025, 26.98% down from the prior year.
  • Non-Current Debt hit $21.8 million in Q4 2025 for Eton Pharmaceuticals, down from $27.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $29.8 million in Q4 2024 to a low of $21.8 million in Q4 2025.